Cargando…

Effects of Obesity on Warfarin Reversal With Vitamin K

Phytonadione (vitamin K1, VK) is fat soluble and may be sequestered by adipose tissue, thus potentially altering drug distribution in obese patients requiring warfarin reversal. This single-center retrospective cohort study aimed to determine the effects of obesity (defined as body mass index [BMI]...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luc, Stanley A., Whitworth, Maegan M., King, Shawna E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714928/ https://www.ncbi.nlm.nih.gov/pubmed/30808216 http://dx.doi.org/10.1177/1076029618824042

Ejemplares similares

Association Between Usual Vitamin K Intake and Anticoagulation in Patients Under Warfarin Therapy
por: Park, Ji Na, et al.
Publicado: (2015)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy
por: Khansari, Nakisa, et al.
Publicado: (2022)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Vitamin K Antagonist Warfarin for Palliative Treatment of Metachromatic Leukodystrophy, A Compassionate Study of Four Subjects
por: Assadi, Mitra, et al.
Publicado: (2012)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Effect of Vitamin K Epoxide Reductase Complex 1 Polymorphism on Warfarin Dose Requirement among Patients in Tertiary Care Hospital
por: Veeregowda, Sahana Hadihalli, et al.
Publicado: (2020)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation
por: Choi, Seong Huan, et al.
Publicado: (2022)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
por: Halvorsen, Sigrun, et al.
Publicado: (2021)

Reversal of Warfarin-Induced Hemorrhage in the Emergency Department
por: Zareh, Meena, et al.
Publicado: (2011)

Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism
por: Saint, Catherine A, et al.
Publicado: (2017)

Vitamin K Deficiency Induced by Warfarin Is Associated With Cognitive and Behavioral Perturbations, and Alterations in Brain Sphingolipids in Rats
por: Tamadon-Nejad, Sahar, et al.
Publicado: (2018)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
por: Shibata, Naoki, et al.
Publicado: (2017)

Real‐life experience with non‐vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
por: Itäinen‐Strömberg, Saga, et al.
Publicado: (2020)

Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
por: Yamkasikorn, Janekij, et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases
por: Golbin, Léonard, et al.
Publicado: (2017)

Effect of vitamin K(2) on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data
por: Zhou, Zhi, et al.
Publicado: (2016)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase
por: Jin, Da-Yun, et al.
Publicado: (2023)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies
por: Xue, Zhengbiao, et al.
Publicado: (2019)

Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
por: Parry‐Jones, Adrian R., et al.
Publicado: (2015)

New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin: One-year follow-up
por: Zhuang, Liying, et al.
Publicado: (2022)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Acute Lower Gastrointestinal Bleeding in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice: Characteristics and Clinical Outcome
por: Diamantopoulou, Georgia, et al.
Publicado: (2019)

Geographic variation in the reversal of vitamin K antagonist-associated coagulopathy
por: Neal, M, et al.
Publicado: (2008)

Budget Impact Analysis of Warfarin Reversal Therapies Among Hip Fracture Patients in Finland
por: Purmonen, Timo, et al.
Publicado: (2015)

Reversal of warfarin anticoagulation in geriatric traumatic brain injury due to ground-level falls
por: Paisley, Michael John, et al.
Publicado: (2019)

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
por: Reddy, Vivek Y., et al.
Publicado: (2018)

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
por: Pan, Kuo‐Li, et al.
Publicado: (2017)

Paradoxical Procoagulant Effect of Early Doses of Warfarin: Possible Role of Non-Vitamin K Oral Anticoagulant in Patients with Atrial Fibrillation-Related Stroke
por: Kim, Yesel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2casrsf0u8k7qi8tj2rbgdq6nm